Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Says Organon Deal Offers Key To Women’s Health Market

Executive Summary

Schering-Plough is looking to build a presence in the women's health care market with the integration of Organon Biosciences

You may also be interested in...



Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles

Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others

Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles

Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others

Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates

Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors

Related Content

UsernamePublicRestriction

Register

PS049321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel